LCMS/MS determination of ginsenoside compound K and its metabolite 20(S)-protopanaxadiol in human plasma and urine: applications in a clinical study / Li Yang, Chun-Yang Wang, Xiao-Nv Xie, Yi-Cheng Wang, Jing-Bo Peng, Wei-Hua Huang, Yao Chen, Dong-Sheng Ouyang, Zhi-Rong Tan
Aim:Ginsenoside compound K (CK) is considered to be a potential therapeutic drug for rheumatoid arthritis because of its good anti-inflammatory activity. The purpose of this work was to establish a rapid, sensitive and specific method for determination of CK and its active metabolite20(S)-protopanaxadiol (20(S)-PPD).Materials& methods:The analytes and internal standards were extracted by liquidliquid extraction. Then, were separated by high performance liquid phase and determined by triple quadrupole mass spectrometry.Results:A LCMS/MS using liquidliquid extraction was developed for determining CK over the concentration range 1.001002.00ng/ml and 0.1554.30ng/ml for 20(S)-PPD. The lower limits of quantification for CK and 20(S)-PPD were 1.00and 0.15ng/ml, respectively.Conclusion:This method was successfully validated for detecting both CK and 20(S)-PPD in the human plasma and urine, and was proved to be suitable for the pharmacokinetic study of CK in healthy Chinese volunteers. Aim: S S Materials& methods: Results: S S Conclusion: S Clinical trial registration number: ChiCTR-TRC-14004824.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Bioanalysis - 11(2019), 05, Seite 365- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Li [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (16 p) |
|---|
| doi: |
10.4155/bio-2018-0185 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL001039512 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL001039512 | ||
| 003 | DE-627 | ||
| 005 | 20230430081456.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210608s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2018-0185 |2 doi | |
| 035 | |a (DE-627)KFL001039512 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/bio-2018-0185 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Yang, Li |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a LCMS/MS determination of ginsenoside compound K and its metabolite 20(S)-protopanaxadiol in human plasma and urine: applications in a clinical study |c Li Yang, Chun-Yang Wang, Xiao-Nv Xie, Yi-Cheng Wang, Jing-Bo Peng, Wei-Hua Huang, Yao Chen, Dong-Sheng Ouyang, Zhi-Rong Tan |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (16 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim:Ginsenoside compound K (CK) is considered to be a potential therapeutic drug for rheumatoid arthritis because of its good anti-inflammatory activity. The purpose of this work was to establish a rapid, sensitive and specific method for determination of CK and its active metabolite20(S)-protopanaxadiol (20(S)-PPD).Materials& methods:The analytes and internal standards were extracted by liquidliquid extraction. Then, were separated by high performance liquid phase and determined by triple quadrupole mass spectrometry.Results:A LCMS/MS using liquidliquid extraction was developed for determining CK over the concentration range 1.001002.00ng/ml and 0.1554.30ng/ml for 20(S)-PPD. The lower limits of quantification for CK and 20(S)-PPD were 1.00and 0.15ng/ml, respectively.Conclusion:This method was successfully validated for detecting both CK and 20(S)-PPD in the human plasma and urine, and was proved to be suitable for the pharmacokinetic study of CK in healthy Chinese volunteers. Aim: S S Materials& methods: Results: S S Conclusion: S Clinical trial registration number: ChiCTR-TRC-14004824 | ||
| 700 | 1 | |a Wang, Chun-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Xiao-Nv |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yi-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Jing-Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Wei-Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Ouyang, Dong-Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Zhi-Rong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d London : Future Science, 2009 |g 11(2019), 05, Seite 365- |h Online-Ressource |w (DE-627)KFL000038172 |w (DE-600)2571813-7 |w (DE-576)398101434 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:05 |g pages:365- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/bio-2018-0185 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 05 |h 365- | ||